Research programme: cancer and diabetes therapeutics - Evotec/Sanofi

Drug Profile

Research programme: cancer and diabetes therapeutics - Evotec/Sanofi

Alternative Names: EVT 601; EVT 701; EVT 801; TargetBCD

Latest Information Update: 26 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Evotec AG; Sanofi
  • Class Cell therapies; Small molecules
  • Mechanism of Action Immunomodulators; Pancreatic beta cell replacements; Vascular endothelial growth factor receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Diabetes mellitus

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 16 Aug 2016 Preclinical trials in Cancer in France (unspecified route) (EVOTEC pipeline - August 2016)
  • 16 Aug 2016 Preclinical trials in Cancer in Germany (unspecified route) (EVOTEC pipeline - August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top